The Goldman Sachs Group, Inc. vs Novartis AG
μκ°μ λ°λ₯Έ μκ°μ΄μ‘ λΉκ΅
The Goldman Sachs Group, Inc.
$255.0B
μμ #56
Novartis AG
$272.5B
μμ #51
μκ°μ λ°λ₯Έ μκ°μ΄μ‘
μ£Όμ μκ°
- The Goldman Sachs Group, Inc.μ΄(κ°) 2025λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2026λ κΉμ§ The Goldman Sachs Group, Inc.μ(λ₯Ό) μΆμνμ΅λλ€
μ°λλ³ λΉκ΅
| μ°λ | The Goldman Sachs Group, Inc. | Novartis AG | μ λ |
|---|---|---|---|
| 2026 | $255.0B | $272.5B | Novartis AG |
| 2025 | $255.6B | $227.3B | The Goldman Sachs Group, Inc. |
| 2024 | $163.2B | $177.6B | Novartis AG |
| 2023 | $107.8B | $163.8B | Novartis AG |
| 2022 | $93.0B | $146.3B | Novartis AG |
| 2021 | $100.5B | $134.5B | Novartis AG |
| 2020 | $68.0B | $134.7B | Novartis AG |
| 2019 | $58.3B | $142.4B | Novartis AG |
| 2018 | $41.5B | $110.8B | Novartis AG |
| 2017 | $62.4B | $104.0B | Novartis AG |
| 2016 | $57.9B | $89.6B | Novartis AG |
| 2015 | $42.9B | $100.4B | Novartis AG |
| 2014 | $45.6B | $103.4B | Novartis AG |
| 2013 | $41.1B | $76.6B | Novartis AG |
| 2012 | $29.2B | $59.2B | Novartis AG |
| 2011 | $20.4B | $52.5B | Novartis AG |
| 2010 | $37.4B | $51.1B | Novartis AG |
| 2009 | $37.2B | $50.7B | Novartis AG |
| 2008 | $18.4B | $44.5B | Novartis AG |
| 2007 | $46.4B | $50.6B | Novartis AG |
| 2006 | $42.8B | $55.9B | Novartis AG |
| 2005 | $27.2B | $53.9B | Novartis AG |
| 2004 | $21.9B | $43.8B | Novartis AG |
| 2003 | $20.6B | $42.0B | Novartis AG |
| 2002 | $14.1B | $36.9B | Novartis AG |
| 2001 | $19.0B | $43.1B | Novartis AG |
| 2000 | $21.8B | $50.7B | Novartis AG |
| 1999 | $19.1B | $40.7B | Novartis AG |